BAO PHARMA-B's stock soared 10.57% during the intraday session, reflecting strong investor interest in the biopharmaceutical company.

The surge appears driven by positive developments in BAO PHARMA's product pipeline, including KJ017 (China's first recombinant human hyaluronidase submitted for market approval), KJ103 (a potentially best-in-class IgG-degrading enzyme for autoimmune diseases), and SJ02 (a long-acting follicle-stimulating hormone for assisted reproduction). These three core products are in commercialization, new drug application review, or late-stage clinical trials, signaling the company's transition from research to commercial stage.

Additionally, a securities firm research report indicates that BAO PHARMA has established a clear commercialization strategy, with products expected to generate significant revenue starting in 2026. KJ017 and SJ02 are forecasted to be primary revenue drivers, while KJ103 is anticipated to contribute from 2027 onward, further boosting investor confidence.